1 Imbrium Therapeutics L.P. (“Imbrium”), a subsidiary of Purdue, sponsored this study. Nalmefene hydrochloride injection is an opioid antagonist indicated for the complete or partial reversal ...

The drug is called Opvee and was approved by the FDA in May of 2023 and is the first Nalmefene nasal spray to be approved. It is another step further in helping fight overdoses both from addiction ...

Nalmefene hydrochloride 1mg/mL (equivalent to 1mg nalmefene base); per vial; soln for IV, IM, or SC inj. IV route preferable: see full labeling. Reversal of opioid effects: see full labeling.

The award from the Biomedical Advanced Research and Development Authority (BARDA) will be used in part to create a stockpile of 200,000 doses of Opvee, the first nalmefene-based nasal spray to be ...

The $20-per-share deal – which values Opiant at around $145 million – will give Indivior rights to OPNT003 (nasal nalmefene), an opioid overdose treatment that, according to the UK company ...

Astute Analytica has released a comprehensive report titled North America & Europe Nalmefene Hydrochloride Market – Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.